The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far.
Marzano, A.V., Genovese, G., Casazza, G., Moltrasio, C., Dapavo, P., Micali, G., et al. (2021). Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study. BRITISH JOURNAL OF DERMATOLOGY, 184(1), 133-140 [10.1111/bjd.18983].
Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study
Sirna, R;Patrizi, A;Dini, V;Bongiorno, M R;
2021-01-01
Abstract
The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
bjd0133.pdf
Solo gestori archvio
Tipologia:
Versione Editoriale
Dimensione
419.6 kB
Formato
Adobe PDF
|
419.6 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
